GLP-2: Effectively Controlling Blood Sugar Levels

By Cocer Peptides      1 month ago

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.

Overview

GLP-2, an innovative medication, has garnered significant attention in the field of metabolism treatment. It is the world's first dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Through its unique mechanism of action, it mimics the natural effects of GLP-1 and GIP, offering a new option for blood glucose control.

Figure 1 Mechanisms of action of GLP-2 within the human body.

Mechanism of Action

Regulation of insulin and glucagon secretion: GLP-2 increases insulin secretion and reduces glucagon release in a glucose-dependent manner. When blood glucose levels rise, GLP-2 prompts pancreatic beta cells to secrete more insulin, thereby accelerating glucose uptake and utilization and lowering blood glucose levels; it also inhibits glucagon secretion, reducing hepatic glucose output, further stabilizing blood glucose levels. This dual-pronged regulatory approach helps maintain dynamic blood glucose balance, effectively lowering both fasting and postprandial blood glucose levels.

Promoting satiety and weight loss: This medication can promote satiety, leading patients to reduce food intake and thereby lose weight. Weight loss is crucial for patients with type 2 metabolism, as obesity is often closely associated with insulin resistance. By reducing weight, GLP-2 helps improve insulin sensitivity, making the body more responsive to insulin and thereby better controlling blood glucose levels. Additionally, weight loss helps reduce the risk of complications such as cardiovascular disease in metabolism patients.

Delaying gastric emptying: GLP-2 delays gastric emptying, prolonging the time food remains in the stomach and slowing its entry into the small intestine, thereby preventing rapid spikes in blood sugar levels. This effect helps stabilize blood sugar fluctuations, particularly by effectively controlling postprandial blood sugar peaks, creating favorable conditions for stable blood sugar control.

Improving metabolic markers: In addition to its effects on blood sugar and weight, GLP-2 also demonstrates positive effects in improving lipid levels and other metabolic markers. Clinical studies indicate that it helps lower low-density lipoprotein (LDL) cholesterol and triglyceride levels, enhancing overall metabolic health and further reducing the risk of cardiovascular disease in diabetic patients.  

Application

In the completed SURPASS and SURMOUNT large-scale Phase III clinical studies, GLP-2 demonstrated superior blood glucose control efficacy. Compared with placebo, GLP-2 significantly reduced hemoglobin A1c (HbA1c) levels while also showing excellent weight loss effects. Its efficacy surpasses that of currently approved GLP-1 receptor agonists. In some trials, patients treated with GLP-2 experienced greater reductions in HbA1c levels and more pronounced weight loss, clearly demonstrating its efficacy and superiority in glycemic control and weight management.

Treatment of Type 2 Diabetes: As an adjunct to diet and exercise, GLP-2 provides an effective treatment option for patients with Type 2 metabolism. Whether used as monotherapy or in combination with other antidiabetic medications, GLP-2 significantly improves patients' blood glucose control.

Conclusion

In summary, GLP-2 demonstrates advantages in blood glucose control due to its unique mechanism of action and outstanding performance in clinical trials. It not only effectively lowers blood glucose levels but also plays a positive role in weight management and improving metabolic markers.

Sources

[1] Sood A, Kaur P, Syed O, et al. Revolutionizing metabolism care: unveiling GLP-2's potential in glycemic  control and beyond[J]. Expert Review of Clinical Pharmacology, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.

[2] Wong E, Cope R, Dima L, et al. GLP-2: A Dual Glucose-dependent Insulinotropic Polypeptide and  Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus[J]. American Journal of Therapeutics, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.

[3] Kumar D, Harshidha D, Mousigan M, et al. An Overview on GLP-2, Dual-Targeted Treatment for Diabetes and Obesity[J]. International Journal of Innovative Research & Growth, 2022,7:983.DOI:10.5281/zenodo.7420605.

[4] Chavda V P, Ajabiya J, Teli D, et al. GLP-2, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review[J]. Molecules, 2022,27(13).DOI:10.3390/molecules27134315.

[5] Forzano I, Varzideh F, Avvisato R, et al. GLP-2: A Systematic Update[J]. International Journal of Molecular Sciences, 2022,23(23).DOI:10.3390/ijms232314631.

Product available for research use only: